Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCMA GPRC5D CAR-T cell therapy - Guangzhou Bio-gene Technology

Next Previous
X
Search
Drug Profile

BCMA GPRC5D CAR-T cell therapy - Guangzhou Bio-gene Technology

Alternative Names: BCMA-GPRC5D CAR-T Cells - Guangzhou Bio-gene Technology

Latest Information Update: 30 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Bio-gene Technology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 30 Jul 2024 Guangzhou Bio-gene Technology initiates a Clinical trial for Multiple Myeloma (Second-line therapy or greater) in China (IV) (NCT06515262)
  • 13 Sep 2023 Phase II clinical trial for Multiple Myeloma in China (IV) (NCT06068400)
  • 25 Aug 2023 BCMA GPRC5D CAR-T cell therapy - Guangzhou Bio-gene Technology is available for licensing as of 25 Aug 2023. http://gzbiogene.com/english.php/Technology/index

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top